About dyne therapeutics inc - DYN
Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
DYN At a Glance
Dyne Therapeutics, Inc.
1560 Trapelo Road
Waltham, Massachusetts 02451
| Phone | 1-781-786-8230 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -446,214,000.00 | |
| Sector | Health Technology | Employees | 258 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DYN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.319 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.37 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.108 |
DYN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,729,511.628 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DYN Liquidity
| Current Ratio | 22.254 |
| Quick Ratio | 22.254 |
| Cash Ratio | 21.937 |
DYN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -47.515 |
| Return on Equity | -55.708 |
| Return on Total Capital | -39.096 |
| Return on Invested Capital | -49.987 |
DYN Capital Structure
| Total Debt to Total Equity | 17.405 |
| Total Debt to Total Capital | 14.825 |
| Total Debt to Total Assets | 14.255 |
| Long-Term Debt to Equity | 16.891 |
| Long-Term Debt to Total Capital | 14.387 |